Literature DB >> 1846331

Beta-blocking effects of timolol at low plasma concentrations.

T Kaila1, R Huupponen, S Karhuvaara, P Havula, M Scheinin, E Iisalo, L Salminen.   

Abstract

The concentration-effect relationship of 0.25 mg intravenous timolol with and without pretreatment with 100 mg quinidine was studied in six healthy young volunteers with a randomized, double-blind, crossover study design. Blockade of cardiac beta-adrenoceptors was assessed by determining the dose ratios (DR) of isoproterenol infusions required to increase heart rate by 25 beats/min before and after timolol infusion. The logarithm of timolol concentration in plasma was linearly related to the logarithm (DR-1) of isoproterenol infusion, with a mean Pearson correlation coefficient of 0.89 +/- 0.11 (+/- SD; n = 24) at timolol concentrations well below 1 ng/ml. The increases in cyclic adenosine monophosphate (cAMP) and norepinephrine plasma levels caused by isoproterenol infusions were attenuated after timolol. Quinidine administration increased timolol plasma levels and cardiac beta-blocking effects by 10% to 40%. It was concluded that timolol at concentrations below 1 ng/ml in plasma competitively antagonizes cardiac and noncardiac effects of isoproterenol infusions. Timolol effects are augmented after quinidine administration. The beta-blockade occurring at low plasma levels can explain side effects and actions of ocularly applied timolol.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846331     DOI: 10.1038/clpt.1991.10

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients.

Authors:  M L Vuori; T Kaila
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-03       Impact factor: 3.117

Review 2.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 3.  Repurposing Ophthalmologic Timolol for Dermatologic Use: Caveats and Historical Review of Adverse Events.

Authors:  Daniel J Yoon; Ramanjot Kaur; Anthony Gallegos; Kaitlyn West; Hsinya Yang; Saul Schaefer; Catherine Tchanque-Fossuo; Sara E Dahle; R Rivkah Isseroff
Journal:  Am J Clin Dermatol       Date:  2020-11-25       Impact factor: 7.403

4.  Evaluation of risk of falls and orthostatic hypotension in older, long-term topical beta-blocker users.

Authors:  Wishal D Ramdas; Nathalie van der Velde; Tischa J M van der Cammen; Roger C W Wolfs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-19       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.